DIPROSONE® 0.05 % W/W CREAM
(Betamethasone Dipropionate)

PRESCRIBING INFORMATION
Refer to Summary of Product Characteristics (SmPC) before prescribing.

Adverse events should be reported. Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard. Adverse events should also be reported to MSD (Tel:
01992-467272).

PRESENTATION
Contains betamethasone 0.05 % w/w as dipropionate.

USES
For topical use in eczema and dermatitis of all types. Also effective in psoriasis of the scalp
and chronic plaque psoriasis of hands and feet but not widespread plaque psoriasis.

DOSAGE AND ADMINISTRATION
Adults and Children: Apply a thin film to affected area once or twice daily.

CONTRAINDICATIONS
Hypersensitivity to any of the ingredients. Rosacea, acne, perioral dermatitis, perianal and
genital pruritis. Presence of tuberculous or most viral lesions of skin. Napkin eruptions,
fungal or bacterial skin infections without suitable concomitant anti-infective therapy.

PRECAUTIONS
Long-term continuous application without interruption should be avoided to reduce the risk
of systemic absorption. Limit use on the face or in children to 5 days. Occlusion must not be
used. In psoriasis, rebound relapse may result from development of tolerance, and due to
impaired barrier function of skin, there is a risk of generalised pustular psoriasis and local
systemic toxicity. Systemic absorption of topical corticosteroids can produce reversible HPA
axis suppression and manifestations of Cushing’s syndrome. Infrequently, signs and
symptoms of steroid withdrawal may occur on discontinuation. Side effects reported with
systemic use of corticosteroids may also occur with topical use. Not for ophthalmic use.
Paediatric patients may be particularly susceptible to adrenal suppression due to a larger skin
surface area to body weight ratio; manifestations of intracranial hypertension have been
reported.

Pregnancy and Lactation: Only use if the potential benefit justifies the potential risk to the
foetus or infant.

SIDE EFFECTS
Refer to Summary of Product Characteristics (SmPC) for complete information on side-
effects. Generally well tolerated and side effects are rare. The following adverse reactions
have been reported: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform
eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of
the skin, secondary infection, striae and miliaria. Continuous application without interruption
may result in local atrophy of the skin, striae and superficial vascular dilation, particularly on
the face.

PACKAGE QUANTITIES AND BASIC NHS COST
Diprosone 5 % w/w cream: 30g: £2.16; 100g: £6.12
Marketing Authorisation Number: PL 00025/0571.
Marketing Authorisation Holder: Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU, UK.

[POM] Date of review of prescribing information: August 2016

© Merck Sharp & Dohme Limited, 2016. All rights reserved.

PI.DPSO-C.16.UK.4869.Var-032